Revelation Biosciences Files 8-K

TL;DR

REV B files 8-K on Jan 17 events - voting, financials, other.

AI Summary

Revelation Biosciences, Inc. filed an 8-K on January 21, 2025, reporting on events that occurred on January 17, 2025. The filing includes information on submission of matters to a vote of security holders, other events, and financial statements and exhibits. The company, formerly known as Petra Acquisition Inc., is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides updates on corporate actions and financial reporting for Revelation Biosciences, Inc., which could impact investor understanding of the company's current status and future plans.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on corporate events and does not appear to contain significant new risks.

Key Players & Entities

• REVELATION BIOSCIENCES, INC. (company) — Registrant
• Petra Acquisition Inc. (company) — Former company name
• January 17, 2025 (date) — Earliest event reported date
• January 21, 2025 (date) — Date of report filing
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
• $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma

Filing Documents

• revb-20250117.htm (8-K) — 79KB
• revb-ex99_1.htm (EX-99.1) — 25KB
• img220778470_0.jpg (GRAPHIC) — 18KB
• 0000950170-25-007303.txt ( ) — 285KB
• revb-20250117.xsd (EX-101.SCH) — 47KB
• revb-20250117_htm.xml (XML) — 7KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 17, 2025, Revelation Biosciences, Inc. (the "Company"), held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders voted and approved proposals to (1) grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a "reverse stock split," at a specific ratio within a range of one-for-2 to a maximum of a one-for-50 split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders, (2) approve the change of domicile of the Company from the State of Delaware to the State of Nevada, (3) approve the reservation and issuance of shares of our common stock pursuant to Class F Common Stock Warrants and Class G Common Stock Warrants (the "Warrants"), dated December 3, 2024, entered into between us and certain purchasers in connection with a warrant inducement letter dated the same date, to the extent that issuances under the Warrants may exceed 20% of the Company's total outstanding shares, which could trigger the share issuance cap under Rule 5635(d) of the Nasdaq Stock Market Rules (the "Exchange Cap") and (4) approve the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the reverse stock split. At the Special Meeting of the Company, a total of 4,139,607 shares of the Company's common stock, out of a total of 6,464,219 shares of common stock issued and outstanding and entitled to vote at the Special Meeting, as of the record date for the Special Meeting, were present virtually, or represented by valid proxy at the Special Meeting, constituting a quorum. As previously described in in the Company's Proxy Sta

01 Other Events

Item 8.01 Other Events. On January 21, 2025, the Company issued a press release titled "Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in Item 8.01 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 21, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: January 21, 2025 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

View Full Filing

View this 8-K filing on SEC EDGAR